🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

12 results for “glargine” Clear

  1. EMPAGLIFLOZIN , DAPAGLIFLOZIN , INSULIN GLARGINE , Placebo to match LY3502970, METFORMIN

    Eli Lilly Co.

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  2. Glargine

    Eli Lilly and Company

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  3. Insulin glargine/Lixisenatide (HOE901/AVE0010)

    Sanofi Pasteur

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  4. albiglutide + insulin glargine

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 3 mab completed

    1 trial

  5. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, METFORMIN , INSULIN DEGLUDEC , INSULIN (HUMAN) , INSULIN GLARGINE , cagrilintide semaglutide, INSULIN DETEMIR , Placebo + Placebo

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  6. INSULIN GLARGINE

    Sanofi-aventis Healthcare Pty Ltd

    Diabetes mellitus II

    approved small molecule active

    1 trial

  7. INSULIN GLARGINE (HOE901)

    Sanofi Pasteur

    Diabetes Mellitus, Type 2

    approved small molecule terminated

    1 trial

  8. Insulin Glargine

    Sanofi Pasteur

    Diabetes Mellitus, Type 2

    approved small molecule completed

    2 trials

  9. Insulin Glargine

    Eli Lilly and Company

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial

  10. SEMAGLUTIDE, SEMAGLUTIDE, INSULIN GLARGINE, DAPAGLIFLOZIN

    Fondazione Telethon ETS

    type 2 diabetes

    approved small molecule active

    1 trial

  11. Subcutaneous glargine insulin

    Lxo Ireland Designated Activity Company

    Diabetes Mellitus

    approved small molecule completed

    1 trial

  12. glargine + exenatide

    Hong Kong Baptist University

    Type 2 Diabetes Mellitus

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources